CIF vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CIF exhibits a stable financial health profile with a Piotroski F-Score of 6/9, though it is caught between a defensive Graham Number of $2.41 and a lower growth-based intrinsic value of $0.98. While the fund trades at a discount to book value (P/B 0.88), it faces significant fundamental headwinds including negative earnings growth (-10.20%) and a highly unsustainable dividend payout ratio of 124.67%. The technical trend is currently bearish (0/100), suggesting that the attractive yield is likely a 'dividend trap' given the lack of earnings coverage.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CIF vs JPM: Head-to-Head Comparison
This page compares MFS Intermediate High Income Fund (CIF) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.